NMPA Tightens AI Medical Device Oversight: CMDE Revises AI Registration Guidance and Issues World's First BCI AI-EEG Dataset Standard
In mid-September 2026, China's Center for Medical Device Evaluation (CMDE) opened public consultation on the revised Artificial Intelligence Medical Device Registration Review Guidance and a new clinical evaluation guidance for AI multi-disease assisted decision devices. Separately, the NMPA published YY/T 2029-2026, the world's first industry standard for AI-processed EEG datasets used in brain-computer interface (BCI) medical devices, effective September 1, 2027.
01CMDE Revises AI Device Registration Guidance
On September 14, 2026, CMDE released the revised Artificial Intelligence Medical Device Registration Review Guidance (2026 Revision) for public comment, with a feedback deadline of October 12, 2026. Two days later, on September 16, CMDE issued a companion clinical evaluation guidance for AI multi-disease assisted decision medical devices. The revision cycle signals that NMPA is raising the bar for algorithm-based device submissions, particularly for standalone AI software and AI-aided diagnostic products. For foreign manufacturers, this means dossier preparation must now explicitly address algorithm iteration, data quality control, and post-market performance monitoring as first-class review items.
02World's First AI-EEG BCI Dataset Standard
On September 14, 2026, the NMPA published industry standard YY/T 2029-2026, the world's first medical device product standard specifying quality requirements and evaluation methods for EEG datasets used to train AI algorithms in brain-computer interface (BCI) devices. The standard takes effect on September 1, 2027, and covers the full data lifecycle—collection, signal processing, annotation, storage, and access—alongside decoding performance assessment. According to the NMPA, BCI devices rely on large volumes of EEG data to train AI models, so dataset consistency and reliability directly affect therapeutic outcomes and patient safety. This is China's third BCI industry standard, following terminology and implantable neurostimulator test-method standards issued in 2025.
03Market Context: Innovation Pipeline Accelerates
The regulatory updates arrive alongside strong market momentum. In August 2026 alone, the NMPA approved 243 medical device products (Announcement No. 90), published on September 16. Meanwhile, China's recently issued 15th Five-Year Pharmaceutical Industry Plan sets a target of more than 200 innovative medical devices launched by 2030, with above-scale pharma and medical device industrial revenue exceeding 3.5 trillion yuan. For the first half of 2026, listed medical device companies posted aggregate revenue of 131.13 billion yuan, up 8.0% year-on-year, with overseas revenue share rising from 35.33% to 38.27%, reflecting continued export growth. For overseas brands entering China, the converging trends of AI regulation, BCI standardization, and policy-driven innovation demand early engagement with the updated guidance.
Want to know how these changes affect your product?
Our regulatory team offers a free assessment with concrete impact analysis within 5 business days.
Free Consultation